<span item_type="fundamental" item_id="16cdcb89d10fa9697030f3fb538a27e2" counter_id="ST/US/COCHW" env="prod"></span><span item_type="announcement" item_id="544252823980280193" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 78 K.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.32.</p><p></p><h3>Segment Revenue</h3><ul><li>Net revenues for the three months ended June 30, 2025, were $78 thousand, an increase of $10 thousand compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>R&amp;D expenses decreased by $0.1 million to $2.485 million for the three months ended June 30, 2025, compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>Sales and marketing expenses decreased by $0.1 million for the three months ended June 30, 2025, compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>General and administrative expenses increased by $0.5 million, primarily due to a $0.3 million severance accrual.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>Operating loss for the three months ended June 30, 2025, was - $5,070 thousand, compared to - $4,852 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>Net loss for the three months ended June 30, 2025, was - $5,690 thousand, compared to - $3,947 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025, was - $8,185 thousand, compared to - $10,235 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>Net cash used in investing activities for the six months ended June 30, 2025, was - $7 thousand, compared to - $899 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>Net cash provided by financing activities for the six months ended June 30, 2025, was $7,992 thousand, compared to $8,664 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Envoy Medical successfully activated all 10 study participants’ fully implanted Acclaim® cochlear implants in the first stage of its pivotal clinical trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li><li>Five Category III CPT codes for totally implantable active middle ear implants, such as the Esteem® device, were approved and became effective on July 1, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>Envoy Medical anticipates substantial patient interest in its fully implanted Acclaim® cochlear implant once approved, positioning it to capture market share as the industry shifts towards fully implanted devices. The company sees potential for renewed opportunities with its FDA-approved Esteem® device, contingent on changes in reimbursement policies.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025069658/ea025090101ex99-1_envoy.htm"></span></p>

ENVOY MEDICAL INC C/WTS 29/09/2028 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 78 K